This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More

DATATRAK Unveils New Branding And New Products At DIA

Stocks in this article: DATA

CLEVELAND, June 25, 2012 /PRNewswire/ -- D ATATRAK International, Inc. (OTCQX: DATA), a technology and services company focused on global eClinical solutions for the clinical trials industry, announces the debut of new corporate branding, new products and the most sophisticated user interface in the industry at the 2012 DIA Annual Meeting in Philadelphia.

(Logo: http://photos.prnewswire.com/prnh/20120625/CL29666LOGO )

Our new branding and logo incorporates our corporate vision of safely accelerating drug, device and biologic development from Concept to Cure ®. This logo represents the collective impact of our new products and product versions introduced last year – uCTMS , uDesign , uEDC , uIRT , uSafety , uTrain and uCDR . All of these products work together seamlessly within a single database, allowing for ease of use and simplicity unmatched in the clinical trials industry.

Our new branding is also prominently reflected throughout the new D ATATRAK ONE™ interface, which harnesses the unique power of our Unified Clinical Research Platform to dramatically upgrade the user experience. Users will experience a feature-rich interface with more intuitive workflows and enhanced mobility.

We are also introducing many other new features in our robust product line but are most proud of our uCTMS product. This product's new features focus on real-time data feeds, reports and imports. Most importantly, this release demonstrates the full potential of the industry's only unified platform by instantly accessing data across any of our products through our robust set of executive dashboards.

"We have eagerly anticipated DIA to showcase our new interface, branding, products and features, which will introduce a paradigm shift in the market," stated Laurence P. Birch, D ATATRAK's Chairman of the Board and CEO. "The new interface is much more than a new look; it's equivalent to giving our customers a new clinical research platform. These enhanced features raise the user experience to new heights, unsurpassed by products on the market today."

Mr. Birch continued, " D ATATRAK is reclaiming its position as the technology leader in the eClinical marketplace – helping our partners bring life saving products to market safely, simply and effectively."

The D ATATRAK ONE™ Clinical Research Platform is an easy to use, cloud-based clinical enterprise solution that assists customers with the strategy, planning and management of their entire life science product portfolio, including resource management, study execution needs and safety reporting. It empowers clinical users and service providers with the components necessary for efficiently designing, delivering and managing clinical trials through the use of seven products – uCTMS, uDesign, uEDC, uIRT, uSafety, uTrain and uCDR.

About D ATATRAK D ATATRAK International is a worldwide technology and services company delivering eClinical solutions and related services for the clinical trials industry. D ATATRAK built its multi-component, comprehensive solution on a single, unified platform and expanded this concept to include services delivery via D ATATRAK's Clinical and Consulting Services™ group. The Company delivers a complete portfolio of software products designed to accelerate the reporting of clinical research data from sites to sponsors and ultimately regulatory authorities, faster and more efficiently than loosely integrated technologies. The D ATATRAK ONE™ software solution, deployed worldwide through an ASP or Enterprise Transfer offering, supports Phase I - Phase IV drug and devices studies in multiple languages throughout the world. D ATATRAK has offices located in Cleveland, Ohio; Bryan, Texas; and Cary (RTP), North Carolina. For more information, visit http://www.datatrak.net.

Except for the historical information contained in this press release, the statements made in this release are forward-looking statements. These forward-looking statements are made based on management's expectations, assumptions, estimates and current beliefs concerning the operations, future results and prospects of the Company and are subject to uncertainties and factors which are difficult to predict and, in many instances, are beyond the control of the Company, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. For a list of certain of the factors that may cause actual results to differ materially from those contemplated in these forward looking statements, please see the Company's report filed with the OTCQX Market on May 10, 2012 announcing its results for the three-month period ending March 31, 2012. The Company undertakes no obligation to update publicly or revise any forward-looking statement whether as a result of new information, future events or otherwise.

SOURCE DATATRAK International, Inc.

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs